IL143092A0 - Stabilization of macrolides - Google Patents

Stabilization of macrolides

Info

Publication number
IL143092A0
IL143092A0 IL14309299A IL14309299A IL143092A0 IL 143092 A0 IL143092 A0 IL 143092A0 IL 14309299 A IL14309299 A IL 14309299A IL 14309299 A IL14309299 A IL 14309299A IL 143092 A0 IL143092 A0 IL 143092A0
Authority
IL
Israel
Prior art keywords
macrolides
stabilization
Prior art date
Application number
IL14309299A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL143092(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL143092A0 publication Critical patent/IL143092A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IL14309299A 1998-12-07 1999-12-06 Stabilization of macrolides IL143092A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds
PCT/EP1999/009521 WO2000033878A2 (en) 1998-12-07 1999-12-06 Stabilization of macrolides

Publications (1)

Publication Number Publication Date
IL143092A0 true IL143092A0 (en) 2002-04-21

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14309299A IL143092A0 (en) 1998-12-07 1999-12-06 Stabilization of macrolides

Country Status (38)

Country Link
US (5) US6605613B2 (cs)
EP (4) EP1137439B2 (cs)
JP (3) JP3805625B2 (cs)
KR (2) KR20060096477A (cs)
CN (2) CN1261163C (cs)
AR (3) AR026102A1 (cs)
AT (1) ATE365051T1 (cs)
AU (1) AU759219B2 (cs)
BE (1) BE1012869A3 (cs)
BR (1) BR9915986A (cs)
CA (3) CA2351580C (cs)
CO (1) CO4980847A1 (cs)
CY (1) CY1106870T1 (cs)
CZ (2) CZ302210B6 (cs)
DE (1) DE69936352T3 (cs)
DK (1) DK1137439T4 (cs)
ES (1) ES2288033T5 (cs)
FR (1) FR2786771B1 (cs)
GB (2) GB9826882D0 (cs)
HK (1) HK1038889B (cs)
HU (2) HU230174B1 (cs)
ID (1) ID29250A (cs)
IL (1) IL143092A0 (cs)
IT (1) IT1319701B1 (cs)
MY (2) MY120594A (cs)
NO (2) NO332698B1 (cs)
NZ (2) NZ511936A (cs)
PE (1) PE20001333A1 (cs)
PL (2) PL196627B1 (cs)
PT (1) PT1137439E (cs)
RU (1) RU2243769C2 (cs)
SG (1) SG151072A1 (cs)
SI (1) SI1137439T2 (cs)
SK (2) SK286688B6 (cs)
TR (2) TR200101416T2 (cs)
TW (2) TWI270550B (cs)
WO (1) WO2000033878A2 (cs)
ZA (1) ZA200104360B (cs)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
CN100338043C (zh) 2002-02-13 2007-09-19 特瓦药厂私人有限公司 从生物物质中提取大环内酯的方法
KR101131794B1 (ko) 2002-07-30 2012-03-30 와이어쓰 엘엘씨 Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
WO2004089958A2 (en) * 2003-03-31 2004-10-21 TEVA Gyógyszergyár Részvénytársaság Crystallization and purification of macrolides
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
PL1558622T3 (pl) 2003-07-24 2008-06-30 Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag Sposób oczyszczania makrolidów
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
EA200601129A1 (ru) * 2003-12-10 2006-10-27 АКРУКС ДиДиЭс ПиТиУай ЭлТиДи Способ лечения нежелательного эффекта при чрескожной доставке лекарства (варианты)
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
CA2581169A1 (en) * 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
WO2006086744A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
RU2008120712A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Способы получения кристаллического рапамицина и определения кристалличности соединений рапамицина при помощи дифференциальной сканирующей калориметрии
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
WO2007075621A1 (en) * 2005-12-20 2007-07-05 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities
CN101605529B (zh) * 2006-02-09 2013-03-13 参天制药株式会社 稳定制剂及它们的制备和使用方法
CN103127100A (zh) 2006-03-23 2013-06-05 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂和方法
AU2011260016B2 (en) 2010-06-02 2013-08-22 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of Rapamycin esters
JP2013529224A (ja) * 2010-06-07 2013-07-18 テリック，インコーポレイテッド 結晶性エザチオスタット塩酸塩非溶媒和物
US9321782B2 (en) * 2010-08-04 2016-04-26 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-O-(heteroalkoxyalkyl) rapamicin compounds with anti-proliferative properties
EP2640730B1 (en) 2010-11-19 2019-08-07 Biocon Limited Processes for preparation of everolimus and intermediates thereof
WO2012170384A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (cs) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
WO2017038612A1 (ja) * 2015-08-28 2017-03-09 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
US20190038605A1 (en) * 2015-09-18 2019-02-07 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
WO2017204215A1 (ja) 2016-05-27 2017-11-30 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
CN115667271A (zh) * 2020-03-27 2023-01-31 波士顿科学国际有限公司 用于使药物结晶的方法
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
CA1338150C (en) † 1988-02-18 1996-03-12 Edward George Howard, Jr. Ceramic/distillable binder compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
ES2258763T3 (es) 1992-10-13 2006-09-01 Wyeth Carbamatos de rapamicina.
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
CZ292233B6 (cs) * 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US6239124B1 (en) * 1996-07-30 2001-05-29 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
EP0975330A1 (en) 1997-02-04 2000-02-02 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
CO4980847A1 (es) 2000-11-27
NZ527781A (en) 2004-11-26
EP1137439B1 (en) 2007-06-20
NO334612B1 (no) 2014-04-22
AU1657300A (en) 2000-06-26
US6852729B2 (en) 2005-02-08
DK1137439T4 (da) 2012-03-19
US20020032213A1 (en) 2002-03-14
CA2732620A1 (en) 2000-06-15
GB9826882D0 (en) 1999-01-27
ID29250A (id) 2001-08-16
RU2243769C2 (ru) 2005-01-10
JP5165199B2 (ja) 2013-03-21
AR026102A1 (es) 2003-01-29
KR20010101128A (ko) 2001-11-14
IT1319701B1 (it) 2003-10-27
US6605613B2 (en) 2003-08-12
CN1876657A (zh) 2006-12-13
CZ20012001A3 (cs) 2001-09-12
NO20121113L (no) 2001-05-16
CA2651609A1 (en) 2000-06-15
NO20012424L (no) 2001-05-16
CZ302210B6 (cs) 2010-12-22
SG151072A1 (en) 2009-06-29
NO332698B1 (no) 2012-12-10
JP3805625B2 (ja) 2006-08-02
HK1038889B (en) 2008-01-25
CN1261163C (zh) 2006-06-28
JP2005200429A (ja) 2005-07-28
ITMI992520A1 (it) 2001-06-02
SI1137439T2 (sl) 2012-05-31
MY127579A (en) 2006-12-29
EP2279751A3 (en) 2011-02-16
MY120594A (en) 2005-11-30
PT1137439E (pt) 2007-09-25
DE69936352D1 (de) 2007-08-02
DE69936352T3 (de) 2012-05-03
CN1374872A (zh) 2002-10-16
HUP0104489A2 (hu) 2002-03-28
ZA200104360B (en) 2002-01-16
EP1137439B2 (en) 2011-11-23
TWI248938B (en) 2006-02-11
PE20001333A1 (es) 2000-12-12
PL348333A1 (en) 2002-05-20
CZ303006B6 (cs) 2012-02-22
AR054444A2 (es) 2007-06-27
US20030191148A1 (en) 2003-10-09
CN1876657B (zh) 2013-01-09
ES2288033T3 (es) 2007-12-16
NO20012424D0 (no) 2001-05-16
TWI270550B (en) 2007-01-11
SI1137439T1 (sl) 2008-06-30
SK286688B6 (sk) 2009-03-05
AU759219B2 (en) 2003-04-10
AR048073A2 (es) 2006-03-29
EP1137439A2 (en) 2001-10-04
US7572804B2 (en) 2009-08-11
TW200540179A (en) 2005-12-16
WO2000033878A2 (en) 2000-06-15
HUP0104489A3 (en) 2004-05-28
JP2002531527A (ja) 2002-09-24
JP5043308B2 (ja) 2012-10-10
JP2006111637A (ja) 2006-04-27
PL196627B1 (pl) 2008-01-31
CA2351580A1 (en) 2000-06-15
US20050107418A1 (en) 2005-05-19
HU230174B1 (hu) 2015-09-28
EP2279751A2 (en) 2011-02-02
SK7662001A3 (en) 2001-12-03
BR9915986A (pt) 2001-09-04
EP1743657A3 (en) 2007-03-28
FR2786771A1 (fr) 2000-06-09
HU228939B1 (en) 2013-07-29
BE1012869A3 (fr) 2001-04-03
FR2786771B1 (fr) 2002-12-27
GB9904934D0 (en) 1999-04-28
HK1038889A1 (en) 2002-04-04
CA2351580C (en) 2012-03-20
TR200101416T2 (tr) 2002-01-21
SK287325B6 (sk) 2010-07-07
KR20060096477A (ko) 2006-09-11
EP1743657A2 (en) 2007-01-17
TR200201428T2 (tr) 2002-12-23
ATE365051T1 (de) 2007-07-15
US7297703B2 (en) 2007-11-20
US7741338B2 (en) 2010-06-22
KR100695834B1 (ko) 2007-03-19
US20080161334A1 (en) 2008-07-03
EP2269651A2 (en) 2011-01-05
PL208854B1 (pl) 2011-06-30
WO2000033878A3 (en) 2000-11-02
US20090270441A1 (en) 2009-10-29
CA2732620C (en) 2013-08-06
ES2288033T5 (es) 2012-04-10
ITMI992520A0 (it) 1999-12-02
EP2269651A3 (en) 2011-03-09
NZ511936A (en) 2003-10-31
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
DE69936352T2 (de) 2008-02-14

Similar Documents

Publication Publication Date Title
IL143092A0 (en) Stabilization of macrolides
IL137024A0 (en) Novel macrolides
PL341647A1 (en) Novel derivatives of erythromycin
PL346544A1 (en) Crystalline forms of eto2
PL340290A1 (en) 2-halogeno-6-0-substituted derivatives of ketolide
TW364383U (en) Improvement on structure of wrist-ball
PL342733A1 (en) Biocement of improved properties
SG83724A1 (en) Novel polyene macrolide compounds and uses
TW399818U (en) Structure of connector
HUP9902855A3 (en) Preparation of sterol- and stanol-esters
AU2003200370A1 (en) Stabilization of macrolides
TW371522U (en) Card-rejection mechanism of connector
AU3898299A (en) Thermal treatment wall
TW398188U (en) Improved structure of de-hooker
TW354479U (en) Improvement of earpick
GB2346031B (en) Adaption of cabling
TW355988U (en) Improved structure for inserting-hook of curtain
TW428810U (en) Improved structure of plug
TW433622U (en) Improved structure of plug
GB9820641D0 (en) Stabilisation of peroxidases
GB9818178D0 (en) Curtain walls
TW364693U (en) Inside structure of plug
PL109021U1 (en) Section of approximately u-shape
TW392981U (en) Improvement of connector
GB9826768D0 (en) Improvements relating to stabilising devices

Legal Events

Date Code Title Description
EXTN Extension order renewed
FF Patent granted
KB Patent renewed
KB Patent renewed
EXP Patent expired